Boehringer Ingelheim (Germany)

Accelerated Hit Identification and Optimization of a Novel Class of Cellularly Active QPCT/L Inhibitors

Abstract QPCT and its Golgi-bound analogue QPCTL catalyze the conversion of N-terminal glutamines into pyroglutamates, a modification that influences diverse biological processes, including Aβ oligomerization, chemokine stabilization, and CD47-SIRPα signaling. Consequently, QPCT/...

Employment status and occupation are associated with liver cirrhosis: A nationwide Swedish case–control study

Abstract Background Liver cirrhosis is often diagnosed in working‐age adults and carries a poor prognosis. A better understanding of variation by employment status and occupation may support earlier and more targeted diagnostic evaluation. Objectives To assess the odds of liver c...

Toward actionable biomarkers in psychiatry: a collaborative roadmap for precision clinical trials. An ACNP position paper

Abstract Psychiatric drug development remains constrained by diagnostic heterogeneity, insufficient and inconsistent drug response, high placebo response rates, and the absence of validated biomarkers that can reliably guide patient stratification, trial design, and regulatory de...

Deciphering senescence-associated mechanisms through cell painting & transcriptomics

Senescence is a key pathomechanism across chronic diseases but also highly heterogeneous. In this study, we demonstrate that high-content imaging and transcriptomics can jointly shed light on senescence in vitro, distinguishing replicative and chemically induced senescence, diffe...

Evaluation of the efficacy and duration of immunity of a bivalent subunit vaccine containing porcine circovirus type 2a and type 2d antigen

Porcine circovirus type 2 (PCV2) vaccination has been effective in protecting pigs from clinical disease and is used extensively today. Studies in vaccinated populations across the world indicate a major PCV2 genotype shift towards genotype 2d (PCV2d) becoming the predominant gen...

Safety, tolerability and pharmacokinetics of an NMDA receptor subunit 2B-selective negative allosteric modulator, BI 1569912: Results of three partially randomised, placebo-controlled phase I trials

Background: BI 1569912 is an orally administered, GluN2B-selective negative allosteric modulator at the N-methyl-D-aspartate receptor. Aims: To investigate the safety, tolerability and pharmacokinetics (PK) of BI 1569912 in healthy males across three partially randomised, placebo...

Ketamine’s impact on rumination-related brain dynamics: insights from a randomized controlled fMRI trial

Abstract Rumination has been associated with aberrant dynamics of a coactivation pattern (CAP) comprising the default mode (DMN) and frontoparietal (FPN) networks. Ketamine exerts rapid antidepressant effects and may influence these dynamics via glutamatergic mechanisms. In a ran...

In-human assessment of target engagement and blockade of radiolabeled BI 765063, an anti-SIRPα antibody

The signal regulatory protein alpha (SIRPα) receptor on myeloid cells binds cluster of differentiation (CD) antigen CD47 on tumor cells, resulting in a “don’t eat me” signal that inhibits phagocytosis. BI 765063, an anti-SIRPα antibody, may restore anti-tumor immunity by blocking...